 | • レポートコード：MRC2108A115 • 出版社/出版日：Mordor Intelligence / 2021年7月26日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、2020年に455.77百万ドルであったデング熱検査の世界市場規模が、2021年から2026年の間に年平均約4.74％成長し、2026年までに597.78百万ドルに達すると予測しています。本調査レポートは、世界のデング熱検査市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品タイプ別（ELISAベース検査、RT-PCRベース検査、デング熱IgG/IgM迅速検査、その他）分析、エンドユーザー別（病院、診断センター、その他）分析、地域別（アジア太平洋、南北アメリカ）分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・デング熱検査の世界市場規模：製品タイプ別（ELISAベース検査、RT-PCRベース検査、デング熱IgG/IgM迅速検査、その他） ・デング熱検査の世界市場規模：エンドユーザー別（病院、診断センター、その他） ・デング熱検査の世界市場規模：地域別（アジア太平洋、南北アメリカ） ・競争状況（Abbott Laboratories、Abnova Corporation、PerkinElmer, Inc (Euroimmun AG)、Certest Biotec S.L.、Diasorin 、F. Hoffmann-La Roche Ltd.、InBios International, Inc.、NovaTec Immundiagnostica GmbH、OriGene Technologies、Thermo Fisher Scientific Inc.） ・市場機会/将来の見通し |
The dengue testing market was valued at USD 455.77 million in 2020 and is expected to reach USD 597.78 million by 2026, registering a CAGR of 4.74% during the forecast period.
Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages. So, most of the people are confusing it to be dengue at getting themselves tested for dengue too. As per the article published in the Journal of Medical Virology in March 2021, dengue has shown an increasing trend in the number of cases in the country, therefore requiring urgent public policies to curb the disease.
The overall incidence of dengue, as well as the explosive outbreaks of dengue, has been increasing dramatically over the last several years. As per the Pan American Health Organization, in the Region of the Americas in 2019, a total of 3,139,335 cases of dengue have been reported, equivalent to 321.58 cases per 100,000 population, including 1,538 deaths. Of the total cases, 1,367,353 were laboratory confirmed and 28,169 were classified as severe dengue.
Although the full global burden of the disease is uncertain, the initiation of activities to record all dengue cases partly explains the sharp increase in the number of cases reported in recent years. Therefore, not only the number of cases is increasing as the disease spreads to new areas, but explosive outbreaks are occurring. Among travelers returning from low- and middle-income countries, dengue is the second most diagnosed cause of fever after malaria. Therefore, the rising prevalence of the dengue virus has raised the demand for more diagnostic kits, which is expected to drive the dengue testing market in the near future.
The government and healthcare professionals are advising people to prevent dengue-carrying mosquitoes, by practicing tried and tested prevention measures, i.e., search and destroy, self-protect, seek early consultation, and say yes to fogging, also termed as the “4S” method. In order to raise awareness regarding the 4S method, the Philippine Red Cross (PRC) conducted a series of campaigns on dengue prevention nationwide for the whole month of June 2018, the dengue awareness month. There is also a change in the climate of European countries that has been a great impact on vector distribution and potential disease transmission. This change in climate is likely to increase the burden of dengue fever, and this, in turn, may propel the growth of the market for dengue testing.
Key Market Trends
ELISA-Based Tests is Expected to Dominate the Product Type Segment During the Forecast Period
Enzyme-linked immunosorbent assay (ELISA) is one of the most common and widely accepted methods for diagnosing dengue. The test measures the presence of anti-DENV IgM or IgG antibodies in patient serum. The early and timely diagnosis and management of dengue has the potential to reduce the risk of morbidity and mortality rates from severe forms of dengue disease as well as decrease the risk of wider outbreaks.
ELISA being the standard method can detect NS1 antigens and has the capability to differentiate between the four dengue virus serotypes. ELISA kits have superior sensitivity when compared to other testing methods. Because of their high sensitivity and efficiency, ELISAs have become the recommended diagnostic choice when laboratories with trained personnel and equipment are available.
Technological advancement in this segment such as robust test kits, offered by several major players in the market is driving the growth of the market. For instance, PANBIO DENGUE IGG INDIRECT ELISA, a test kit offered by Abbott is used to detect IgG antibodies to dengue antigen serotypes (1, 2, 3, and 4) in serum as an aid to clinical laboratory diagnosis of patients with clinical symptoms and past exposure consistent with dengue fever. Another test kit offered by InBios International Inc. is DENV Detect NS1 ELISA Kit, which is also used for the early detection of dengue virus (DENV) NS1 antigen in human serum. Thus, considering all the above-mentioned factors, the market is expected to witness steady growth over the forecast period.
Asia Pacific is Fastest Growing Market in the Dengue Testing Market
Asia Pacific is found to be the fastest growing market in the global dengue testing market as there are millions of cases of dengue infection every year. The number of dengue cases is increasing each year. For instance, according to the article published in 2019 by Qinlong Jing et al, it was found that, in recent years, southern China has been experiencing a high frequency of transmission and recurring epidemics of dengue, especially in Guangzhou, which accounts for 69.2% of reported cases in mainland China.
Moreover, according to a report published by the Directorate of National Vector Borne Disease Control Program 2019, a total of 67,377 cases of dengue and 48 deaths due to the vector-borne disease have been reported from across India as of October 2019. Dengue is the most prevalent and rapidly spreading mosquito-borne viral disease.
Moreover, the recent dengue outbreak in various regions in Asia-Pacific indicates that there may be increased risks for future dengue outbreaks in these countries, due to the influx of dengue viruses from overseas combined with the increase in vector population and the expansion of the habitats caused by climate changes, resulting in the rising cases of dengue in Asia-Pacific.
According to the article published in 2018 by Y Kajimoto et al, it was found that the average number of dengue patients is about 274 per year in Japan, and the average economic burden was approximately USD 830,626 per year. The economic burden of dengue fever and dengue hemorrhagic fever per patient was about USD 2,093 and USD 11,536, respectively in Japan. Thus, considering all the above-mentioned factors, as the number of patients is rising in this region, the testing of the dengue is also expected to rise and boost the growth of the market.
Competitive Landscape
There has been a presence of a considerable number of companies that are significantly contributing to market growth. Recently the Telenor Heath’s Tonic has launched “Home Diagnostic Tests” service for dengue with video consultation through their “Tonic App”. The major companies that are functioning in the global dengue testing market include Abbott Laboratories, NovaTec Immundiagnostica GmbH, Euroimmun AG (PerkinElmer), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and InBios International, Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase Incidences of Dengue Cases
4.2.2 Increasing Awareness Campaigns to Educate About the Ills of Dengue
4.3 Market Restraints
4.3.1 Unavailability of Effective Diagnostic Tools
4.3.2 High Price of Existing Test Kits
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 ELISA-based Tests
5.1.2 RT-PCR based Tests
5.1.3 Dengue IgG/IgM Rapid Test
5.1.4 Other Tests
5.2 By End User
5.2.1 Hospitals
5.2.2 Diagnostic Centers
5.2.3 Others
5.3 Geography
5.3.1 Asia Pacific
5.3.1.1 India
5.3.1.2 Philippines
5.3.1.3 Indonesia
5.3.1.4 Malaysia
5.3.1.5 Vietnam
5.3.1.6 Thailand
5.3.1.7 Sri Lanla
5.3.1.8 Rest of Asia-Pacific
5.3.2 Americas
5.3.2.1 Brazil
5.3.2.2 Mexico
5.3.2.3 Nicaragua
5.3.2.4 Colombia
5.3.2.5 Honduras
5.3.2.6 Rest of Americas
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Abnova Corporation
6.1.3 PerkinElmer, Inc (Euroimmun AG)
6.1.4 Certest Biotec S.L.
6.1.5 Diasorin
6.1.6 F. Hoffmann-La Roche Ltd.
6.1.7 InBios International, Inc.
6.1.8 NovaTec Immundiagnostica GmbH
6.1.9 OriGene Technologies
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS